Biorbis

New technological advances in vaccine research and development are set to revolutionise the industry.

Dr Jeffrey Ulmer Global Head of External Research Novartis Vaccines and Diagnostics	Dr Kathrin Jansen Senior Vice President, Vaccine Research and Early Development Pfizer	Dr Danilo Casimiro Director and Head, Viral Vaccine Research, Vaccine Basic Research Merck & Co.
Dr George Kemble Vice President, Research and Development MedImmune	Dr Jens-Oliver Funk Senior Vice President, Global Head of Therapeutic Area Oncology Merck Serono	Dr Alexander von Gabain Strategic Advisor to the Management and Supervisory Boards Intercell AG
Dr Jean-Yves Bonnefoy Vice President Research and Development Transgene	Dr Jessica Flechtner Senior Director Research and Development Genocea Biosciences	Dr Jerald Sadoff Dr Jerald Sadoff Aeras Global TB Vaccine Foundation
Dr Christoph Huels Vice President Early Stage Licensing Merck Serono	Dr Thomas Hofstaetter Chief Operations Officer VaxInnate	Dr Martin Bachmann Chief Scientific Officer Cytos Biotechnology
Dr Christian Moser Head of Research Pevion Biotech	Dr Alfredo Nicosia Chief Scientific Officer Okairos	Dr Heather Davis Executive Director and Ottawa Site Head, Vaccine Research Pfizer Global Research & Development
Dr Guido Grandi Senior Project Leader Novartis Vaccines and Diagnostics	Dr Jon Heinrichs Senior Research Fellow Merck & Co.	Gerd Stoetter European Patent Attorney Kailuweit & Uhlemann
Dr Bruno Guy, Director of Immunology and Expert Scientist, Discovery Research, Sanofi-Pasteur Dr Kingston Mills, Co-founder, Opsona Therapeutics Ltd Dr Steen Klysner, Chief Executive Officer, Nordic Vaccine Dr Michael Wacker, Chief Scientific Officer, GlycoVaxyn Dr William Enright, Chief Executive Officer, Vaxin Paul Radspinner, Chief Executive Officer, Flugen

Designed by the likes of Novartis, Pfizer, Merck, GSK, MedImmune, Sanofi Pasteur, Intercell and a host of others, the Biorbis Vaccine Innovation meeting will focus on the robust research behind new innovative technologies to develop more effective vaccines.

Different to any other vaccine event you've attended before, and incorporating a dynamic line-up of speakers , you will leave with a host of new ideas and contacts to improve your business and research.

Who is Speaking? Three not-to-miss presentations!

• Hear from Novartis as Jeffrey Ulmer describes the cutting edge advances in antigen development that are set to transform vaccines. What does this mean for your business?
• Danny Casimiro shows how you can follow Merck's lead and start tapping into the huge potential of subunit vaccines.
• Effectively utilising adjuvants can maximise the potential of your vaccine candidates explains Pfizer's Heather Davis.

Do you want more? See the whole blockbuster line up for Vaccine Innovation in the full agenda.

What's covered on the agenda?

• New methodologies for identification of antigenic targets and how to incorporate this into effective vaccine design.
• Applying structure-based approaches to create new innovative vaccines: Novel vector technologies, subunit vaccines and glyco-conjugates.
• Utilising next generation adjuvants to improve poor immunogenicity by stimulating a robust immune response.
• Investigating innovative vaccine design & delivery methods including vaccine patch technology and other alternatives to needle-based immunisation.

Find out for yourself by downloading a brochure here.

1-2-1 Partnering

We work harder than any other meeting organizer to put you in front of the individuals you want to meet, providing personal introductions and a host of other networking opportunities including:

• Speed networking – Meet up to 50 other attendees in a one hour session. Introduce yourself to potential partners, collaborators and clients.
• Over 8 hours of networking time built into the agenda
• Innovative masterclasses providing you with the chance to get tailored solutions to the challenges you're facing.
• Panel discussion – interactive Q&A sessions giving you an opportunity to join the discussion.